Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607983 | 0.90 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL261247 | 0.83 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL31298376 | 0.81 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL31298390 | 0.80 | SMYD2 (0.41) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL25364479 | 0.78 | RIPK1 (0.42) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL2146189 | 0.78 | RIPK1 (0.42) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL25365732 | 0.78 | RIPK1 (0.42) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL18587707 | 0.78 | RIPK1 (0.42) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL18587235 | 0.77 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL2795827 | 0.77 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144760-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144760-A1 | NOVEL COMPOUNDS | HTR3B, HTR1B, HTR2B | SMYD2 3421/4885CYP3A4 60/4885HTT 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.